The Municipal Health Commission's "Four Links" Study Finds Outstanding Problems and Seeks Innovation to Assist the Development Foundation of Shanghai's Biomedical Industry | Clinical | Municipal Health Commission
The biopharmaceutical industry is one of the three leading industries in Shanghai. On the 15th, the Party Group of the Municipal Health Commission conducted extensive research in the early stage, focusing on improving the clinical research system of the city, enhancing the clinical research capabilities of medical and health institutions, and promoting the high-quality development of Shanghai's health industry and biopharmaceutical industry. They carried out "joint learning, joint research, joint rectification, and joint development" learning and exchange. At the meeting, it was reported that the Municipal Health Commission will improve the clinical research system, assist in the development of the biopharmaceutical industry, create a highland for medical development, and seek breakthroughs and innovations as a key topic.
Technology is the primary productive force, talent is the primary resource, and innovation is the primary driving force. In recent years, the Municipal Health Commission has taken the "national municipal hospital" clinical research network as the overall layout, continuously optimizing the clinical research policy environment, focusing on disciplinary talent construction, promoting achievement transformation, leveraging resources from all parties, and promoting high-quality clinical research and clinical trials in medical institutions.
Many hospitals in Shanghai have strong capabilities, abundant clinical resources, and solid scientific research foundations. They focus on the construction of research-oriented hospitals, rely on the National Medical Center, create characteristic key specialties and key discipline groups, strengthen the diagnosis and treatment of critical and difficult diseases, and enhance clinical research and medical technology innovation capabilities.
For example, Shanghai Jiao Tong University and Ruijin Hospital, as the main body of the national major scientific and technological infrastructure for translational medicine, have formed a large-scale equipment scale, integrated core functions, and systematic technical capabilities facility technology system, connecting the complete technology chain of translational medicine research from basic to clinical upstream and downstream. Zhongshan Hospital has applied for over 2400 patents and granted over 1200 patents in the past 10 years, with a total amount exceeding 178 million yuan. The Ninth People's Hospital is characterized by the intersection of medical and industrial fields, with a focus on building an innovative research and development center for medical 3D printing, a precision medicine research institute, and a clinical research center for surgical robots.
Overall, relying on the advantages of high-quality medical resources and talent, Shanghai has achieved remarkable results in medical innovation, clinical research, and transformation with the joint support of various departments, and is at the forefront of the country.
Data shows that in 2021, a total of 8 types of domestically produced innovative drugs were approved in this city, accounting for nearly one-fifth of the total number in the country and ranking among the top in the country. In 2022, there were a total of 3219 Phase I-III clinical trials of drugs under study in this city, a year-on-year increase of 21%. In 2022, a total of 4 varieties of domestically produced innovative drugs were approved in this city, ranking first in the country.
From 2018 to 2022, a total of 51 products in Shanghai entered the national special review process for innovative medical devices, accounting for 18.2% of the national total; 28 innovative medical device registration certificates have been approved, accounting for 17.9% of the national total. Some product technologies have filled the gap in domestic related fields and reached the international advanced level. However, there is still a certain gap in the requirements for building technology innovation centers with global influence.
Managers from multiple medical institutions have had in-depth exchanges on improving the clinical research system in this city and enhancing the clinical research capabilities of medical and health institutions. Wen Daxiang, Secretary of the Party Group and Director of the Municipal Health Commission, stated that technological innovation adheres to "facing the forefront of world science and technology, the main battlefield of the economy, the major needs of the country, and the life and health of the people." The Municipal Health Commission, in conjunction with theme education and relevant departments, plans and collaborates systematically to build the Shanghai medical and health industry into the main battlefield of medical innovation, gradually guiding powerful hospitals to focus on difficult and complex diseases, cutting-edge technology, and technological innovation, and forging the main force of medical innovation.